GlobeNewswire
-
Abivax Provides 2026 Corporate Outlook
07/01/2026 -
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
07/01/2026 -
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
07/01/2026 -
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
07/01/2026 -
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026 -
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
07/01/2026 -
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
07/01/2026 -
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026 -
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026 -
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026 -
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
07/01/2026 -
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
07/01/2026 -
4DMT Provides Company Update and Anticipated Development Milestones for 2026
07/01/2026 -
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
07/01/2026 -
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026 -
Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/01/2026 -
Ipsen - Décembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/01/2026 -
300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition
07/01/2026 -
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
07/01/2026
Pages